Effect of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas

J Pathol. 1997 Dec;183(4):460-8. doi: 10.1002/(SICI)1096-9896(199712)183:4<460::AID-PATH961>3.0.CO;2-Z.

Abstract

Interleukin-6 (IL-6) has been shown to be released by cultured human meningioma cells and may be a positive or negative regulator of tumour growth. IL-6 protein and mRNA levels have been examined in a series of meningiomas. In 14 cases, the results are compared with the effects of IL-6 and dexamethasone on growth and IL-6 secretion in vitro. Tumours with the highest in vivo IL-6 mRNA expression also showed maximum induction of IL-6 and increased cellular proliferation on IL-1 stimulation in vitro. Dexamethasone decreased the IL-1-stimulated IL-6 release in all cases. Meningiomas which had little or no IL-6 message were refractory to IL-1 control of IL-6. Remarkably, these formed the group of meningiomas that increased their growth rate in response to dexamethasone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cell Division / drug effects
  • Dexamethasone / pharmacology*
  • Female
  • Glucocorticoids / pharmacology*
  • Humans
  • In Situ Hybridization
  • Interleukin-1 / pharmacology*
  • Interleukin-6 / biosynthesis*
  • Interleukin-6 / genetics
  • Male
  • Meningioma / metabolism*
  • Meningioma / pathology
  • Middle Aged
  • RNA, Messenger / genetics
  • Tumor Cells, Cultured

Substances

  • Glucocorticoids
  • Interleukin-1
  • Interleukin-6
  • RNA, Messenger
  • Dexamethasone